No Data
No Data
Hybio Pharmaceutical Gets Nod to Market Somatostatin in Europe
Hybio Pharmaceutical (300199.SZ): The active pharmaceutical ingredient of somatostatin has obtained the CEP certificate.
On September 4th, Hybio Pharmaceutical (300199.SZ) announced that the company's somatostatin active pharmaceutical ingredient has received the CEP certificate (Certificate of Suitability to the European Pharmacopoeia) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Somatostatin is a cyclic peptide consisting of fourteen amino acids that is artificially synthesized and has the same chemical structure and mechanism of action as natural somatostatin. Physiological somatostatin is mainly found in the hypothalamus and gastrointestinal tract. Intravenous administration of somatostatin can: 1) inhibit the secretion of growth hormone, thyroid-stimulating hormone, insulin, and glucagon; and 2) inhibit the secretion of gastric acid.
Hybio Pharmaceutical: Summary of Half-Year Report in 2024.
Hybio Pharmaceutical: Half-year report for the year 2024.
Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations
①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.
hybio pharmaceutical (300199.SZ): net loss of 10.3588 million yuan in the first half of the year.
Hybio Pharmaceutical (300199.SZ) announced the interim report for the first half of 2024, with reported revenue of 0.256 billion yuan, a year-on-year decrease of 21.38%; net income attributable to shareholders of the listed company was -10.3588 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -59.7238 million yuan; basic earnings per share was -0.01 yuan.
No Data
No Data